Susanna Naggie, MD

Associate Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, 6th Floor - 6410, Durham, NC 27701
Phone (919) 684-2584
Email address susanna.naggie@duke.edu

Dr. Susanna Naggie completed her medical education at Johns Hopkins School of Medicine and her internal medicine training at Duke University Medical Center (DUMC), where she also served as a Chief Resident in Internal Medicine.  She completed her Infectious Diseases (ID) fellowship training at Duke and then joined the faculty in the Division of ID. She is an Associate Professor of Medicine with Tenure and currently holds joint appointments at the Duke Clinical Research Institute (DCRI, Director of ID Research), and at the Durham Veterans Affairs Medical Center (DVAMC). Dr. Naggie has dedicated her academic career to the care of patients with HIV and viral hepatitis, with a research program focused on understanding the mechanisms of accelerated liver fibrogenesis in this population and the extrahepatic health outcomes attributed to HCV in persons with HIV infection. In addition to her investigator-initiated research program, Dr. Naggie is also involved in multiple clinical trials and clinical registries with a particular focus on HIV and liver disease. She is the prior co-Chair of the AASLD/IDSA HCV Guidance Committee and is currently Chair of the AIDS Clinical Trials Group Viral Hepatitis Transformative Science Group Committee and a member of the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee. For the past two years Dr. Naggie has served as the Medical Director of the Duke Department of Medicine Clinical Research Unit.

Education and Training

  • Fellow in Infectious Diseases, Medicine, Duke University, 2007 - 2009
  • Chief Medical Resident - VAMC, Medicine, Duke University, 2006 - 2007
  • Medical Resident, Medicine, Duke University, 2002 - 2005
  • M.D., Johns Hopkins University, 2002

Publications

Naggie, Susanna, Meredith Clement, Sam Lusk, Anu Osinusi, Tiffany Himmel, Joseph E. Lucas, Will J. Thompson, et al. “Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations..” Proteomics Clin Appl 13, no. 3 (May 2019). https://doi.org/10.1002/prca.201800006.

PMID
30058111
Full Text

Zuckerman, Eli, Julio Gutierrez, Andrew Ustianowski, Susanna Naggie, Florin Alexandru Caruntu, Natarajan Ravendhran, Samuel Sigal, et al. “Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies.” In Journal of Hepatology, 70:E251–E251. ELSEVIER SCIENCE BV, 2019.

Scholars@Duke

Zuckerman, Eli, Julio Gutierrez, Andrew Ustianowski, Susanna Naggie, Florin Alexandru Caruntu, Natarajan Ravendhran, Samuel Sigal, et al. “Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies.” In Journal of Hepatology, 70:E251–E251. ELSEVIER SCIENCE BV, 2019.

Scholars@Duke

Naggie, Susanna, and Christian B. Ramers. “Sustained Virologic Response in People Who Inject Drugs and/or Who Are on Opioid Agonist Therapy: Is 90% Enough?.” Hepatol Commun 3, no. 4 (April 2019): 453–55. https://doi.org/10.1002/hep4.1347.

PMID
30976736
Full Text

Naggie, Susanna. “Treating HCV Infection: It Doesn't Get Much Better Than This..” Top Antivir Med 26, no. 4 (January 2019): 104–8.

PMID
30641483
Scholars@Duke

Chan, Austin, Lawrence Park, Lauren F. Collins, Curtis Cooper, Michael Saag, Douglas Dieterich, Mark Sulkowski, and Susanna Naggie. “Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ß2M in the ION-4 Study Cohort..” Open Forum Infect Dis 6, no. 1 (January 2019). https://doi.org/10.1093/ofid/ofy273.

PMID
30697570
Full Text

AASLD-IDSA HCV Guidance Panel, Jennifer L. “Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection..” Clin Infect Dis 67, no. 10 (October 30, 2018): 1477–92. https://doi.org/10.1093/cid/ciy585.

PMID
30215672
Full Text

Muir, Andrew Joseph, Jia Yao, Julius Wilder, Christina Makarushka, Kelly Keefe, James Henry Helzberg, Paolo Mannelli, et al. “The Alcohol Use Disorders Identification Test Screening in Patients with Hepatitis C.” In Hepatology, 68:908A-908A. WILEY, 2018.

Scholars@Duke

Clement, Meredith, Mira Nicchitta, Alicia Ellis, Sarah Hale, Hrishikesh Chakraborty, Kara McGee, Cedar Eagle, et al. “Outcomes for PrEP Users in the Southern US: Persistence and STIs.” In Aids Research and Human Retroviruses, 34:258–258. MARY ANN LIEBERT, INC, 2018.

Scholars@Duke

Pages